A Phase 3 interventional study of Dulaglutide and Placebo in Type 2 Diabetes, sponsored by Eli Lilly and Company. Completed at 61 sites in 11 countries. Open to participants aged 10 Years to 17 Years. Per ClinicalTrials.gov, last updated 2022-07-01.
Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 54 studies testing dulaglutide in Diabetes Mellitus, Type 2 — 3 open to participants now, 4 under way, 1 of them phase 3. dulaglutide · Diabetes Mellitus, Type 2.
Among the 54 studies testing dulaglutide in Diabetes Mellitus, Type 2, this one is the 29th largest by enrollment, is one of 3 that started in 2016, is one of 22 in phase 3, and was the 32nd registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →3 of the 54 studies testing dulaglutide in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:
Eli Lilly and Company · Sites in United States, Argentina, Mexico
Ages 10–17
First Affiliated Hospital of Wannan Medical College
Ages 18+
Seoul National University Bundang Hospital
Ages 20–90
By country, each count listing its studies:
dulaglutide: first FDA approval 2014 (TRULICITY), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.
This study: 10 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
54 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 15 · Phase 2 6 · Phase 3 23 · Phase 4 9
First in 2008; this study’s year is marked. 3 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 154 is above the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 159 across the 54 interventional studies. Of the 47 that completed or were terminated, 38 (81%) have results posted.
This tab as a report to print or save as PDF → With an account.
45 of 54 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
238 studies in Diabetes Mellitus, Type 2 by Eli Lilly and Company: 10 open now, 21 under way, 11 of them phase 3. Of 211 finished, 155 (73%) have results posted.
Among the 238 studies in Diabetes Mellitus, Type 2 by Eli Lilly and Company, this one is the 122nd largest by enrollment of the 232 interventional ones that give a count, is one of 7 that started in 2016, is one of 85 in phase 3, and was the 123rd registered.
Eli Lilly and Company’s Diabetes Mellitus, Type 2 studies by the year they started, since 2001.
1 of the studies testing dulaglutide in Diabetes Mellitus, Type 2 that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07537088First Affiliated Hospital of Wannan Medical CollegeEfficacy and Safety of Triple Therapy With Dulaglutide, SGLT2 Inhibitors, and Finerenone in Chinese Adults With Type 2 Diabetes and Chronic Kidney Disease | 2027-04 |
Add it to your calendar (.ics) → With an account.
Among the 54 studies testing dulaglutide in Diabetes Mellitus, Type 2, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Eli Lilly and Company’s 238 in Diabetes Mellitus, Type 2:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the safety, efficacy, pharmacokinetics and pharmacodynamics of the study drug dulaglutide compared to placebo in pediatric participants with type 2 diabetes. The study duration is approximately 60 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received placebo administered subcutaneously (SC) for 26 weeks during the double-blind period and open-label 0.75 mg/week dulaglutide for 26 weeks during the Open Label Extension (OLE).
Drug: Dulaglutide · Drug: Placebo
Participants received 0.75 mg/week dulaglutide administered SC for 26 weeks during the double-blind period and open-label 0.75 mg/week for 26 weeks during the OLE.
Drug: Dulaglutide
Participants received 1.5 mg/week dulaglutide administered SC for 26 weeks during the double-blind period and open-label 1.5 mg/week for 26 weeks during the OLE.
Drug: Dulaglutide
Administered SC
Also known as: LY2189265
Administered SC
Change From Baseline in Hemoglobin A1c (HbA1c) (Pooled Doses) at Week 26
HbA1c is a form of hemoglobin that is measured primarily to identify the average plasma glucose concentration over prolonged periods of time. Least square (LS) mean in HbA1c was calculated using a restricted maximum likelihood (REML) based mixed-effects model for repeated measures (MMRM) and adjusted by, baseline + insulin Use + metformin Use + treatment + time + treatment\*time (Type III sum of squares). Variance-covariance structure = unstructured (for actual value) / unstructured (for change from baseline).
Time frame: Baseline, Week 26
Change From Baseline in HbA1c (Individual Doses) at Week 26
HbA1c is a form of hemoglobin that is measured primarily to identify the average plasma glucose concentration over prolonged periods of time. LS mean in HbA1c was calculated using a REML based MMRM and adjusted by, baseline + insulin use + metformin use + treatment + time + treatment\*time (Type III sum of squares). Variance-covariance structure = unstructured (for actual value) / unstructured (for change from baseline).
Time frame: Baseline, Week 26
Change From Baseline in Fasting Blood Glucose (FBG) at Week 26
Fasting blood glucose is a test to determine how much glucose (sugar) is in a blood sample after an overnight fast. Least squares (LS) means were calculated using a mixed-effects model for repeated measures (MMRM) analysis and adjusted by baseline, strata, treatment, time, treatment\*time, (Type III sum of squares). Variance-Covariance structure = Unstructured (for actual value) / Unstructured (for change from baseline). Strata refer to: insulin use + metformin use + baseline HbA1c group \[ less than (\<) 8%, greater than or equal to (\>=) 8%).
Time frame: Baseline, Week 26
Percentage of Participants With HbA1c ≤7.0%
The percentage of participants was calculated by dividing the number of participants reaching target HbA1c by the total number of participants analyzed, multiplied by 100.
Time frame: Week 26
Change From Baseline in Body Mass Index (BMI) at Week 26
BMI is an estimate of body fat based on body weight divided by height squared. LS mean were calculated using a MMRM analysis and adjusted by baseline, strata, treatment, time, treatment\*time, (Type III sum of squares). Variance-Covariance structure = Unstructured (for actual value) / Unstructured (for change from baseline). Strata refer to: insulin use + metformin use + baseline HbA1c group (\< 8%, \>= 8%).
Time frame: Baseline, Week 26
Percentage of Participants With Self-Reported Events of Hypoglycemia
Summary and analysis of Incidence of all hypoglycemia with Plasma Glucose \<54mg/dL.
Time frame: Week 26
Percentage of Participants Requiring Rescue for Severe, Persistent Hyperglycemia
Percentage of Participants Requiring Rescue for Severe, Persistent Hyperglycemia was summarized.
Time frame: Week 26
Number of Participants With Adjudicated Pancreatitis
The number of participants with pancreatitis confirmed by adjudication is summarized cumulatively at 26 weeks. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.
Time frame: Week 26
Change From Baseline in Pancreatic Enzymes at Week 26
Serum Amylase (total and pancreas-derived) and lipase concentrations were measured.
Time frame: Baseline, Week 26
Number of Participants With Thyroid Treatment-Emergent Adverse Events
Number of Participants with Thyroid Treatment-Emergent Adverse Events were summarized.
Time frame: Week 26
Change From Baseline in Serum Calcitonin at Week 26
Change from Baseline in Serum Calcitonin was evaluated.
Time frame: Baseline, Week 26
Percentage of Participants With Allergic, Hypersensitivity Reactions
The percentage of Participants with Allergic and hypersensitivity reactions that were considered possibly related to study drug by the investigator are presented. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.
Time frame: Week 26
Percentage of Participants With Injection Site Reactions
The percentage of participants with at least one treatment-emergent injection site reaction is presented. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.
Time frame: Week 26
Number of Participants With Anti-Dulaglutide Antibodies
Dulaglutide anti-drug antibodies (ADA) were assessed at baseline, Weeks 26 and 56. A participant was considered to have treatment-emergent (TE) dulaglutide ADAs if the participant had at least 1 titer that was TE relative to baseline, defined as a 4-fold or greater increase in titer from baseline measurement.
Time frame: Baseline through Week 56
Pharmacokinetics (PK): Maximum Concentration of Dulaglutide at Steady-state (Cmax,ss)
PK: Maximum Concentration of Dulaglutide at steady-state (Cmax,ss) was derived by a population pharmacokinetics approach. As part of addendum, additional PK samples were taken at week 9.
Time frame: Week 9: pre-dose,1 to 12 hours post dose and 24 to 96 hours post dose; Week 13: predose and 1 to 12 hours post dose; Week 26: predose; Week 39: up to 2 days postdose; Week 52 and Week 56: PK sample can be taken at any time during the visit
PK: Area Under the Concentration Time Curve Over a 1-week Interval of Dulaglutide at Steady-State [AUC(0-168)ss]
PK: Area Under the Concentration Time Curve over a 1-week interval of Dulaglutide at Steady-State \[AUC(0-168)ss\] was derived by a population pharmacokinetics approach. As part of addendum, additional PK samples were taken at week 9.
Time frame: Week 9: pre-dose,1 to 12 hours post dose and 24 to 96 hours post dose; Week 13: predose and 1 to 12 hours post dose; Week 26: predose; Week 39: up to 2 days postdose; Week 52 and Week 56: PK sample can be taken at any time during the visit
| Milestone | Placebo/0.75 Milligram (mg) Dulaglutide | 0.75 mg Dulaglutide | 1.5 mg Dulaglutide |
|---|---|---|---|
| Started | 51 | 51 | 52 |
| Received at least 1 dose of study drug | 51 | 51 | 52 |
| Completed | 47 | 49 | 50 |
| Not completed | 4 | 2 | 2 |
| Withdrew: Adverse event | 1 | 0 | 1 |
| Withdrew: Physician decision | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 1 | 1 | 0 |
| Withdrew: Withdrawal by parent or guardian | 0 | 0 | 1 |
| Withdrew: Protocol violation | 1 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 1 | 0 |
| Milestone | Placebo/0.75 Milligram (mg) Dulaglutide | 0.75 mg Dulaglutide | 1.5 mg Dulaglutide |
|---|---|---|---|
| Started | 47 | 49 | 50 |
| Completed | 45 | 46 | 48 |
| Not completed | 2 | 3 | 2 |
| Withdrew: Physician decision | 1 | 2 | 2 |
| Withdrew: Withdrawal by subject | 1 | 1 | 0 |
HbA1c is a form of hemoglobin that is measured primarily to identify the average plasma glucose concentration over prolonged periods of time. Least square (LS) mean in HbA1c was calculated using a restricted maximum likelihood (REML) based mixed-effects model for repeated measures (MMRM) and adjusted by, baseline + insulin Use + metformin Use + treatment + time + treatment\*time (Type III sum of squares). Variance-covariance structure = unstructured (for actual value) / unstructured (for change from baseline).
| percentage of HbA1C | Placebo | Pooled Dulaglutide |
|---|---|---|
| Change From Baseline in Hemoglobin A1c (HbA1c) (Pooled Doses) at Week 26 | 0.5 ± 0.24 | -0.7 ± 0.16 |
HbA1c is a form of hemoglobin that is measured primarily to identify the average plasma glucose concentration over prolonged periods of time. LS mean in HbA1c was calculated using a REML based MMRM and adjusted by, baseline + insulin use + metformin use + treatment + time + treatment\*time (Type III sum of squares). Variance-covariance structure = unstructured (for actual value) / unstructured (for change from baseline).
| percentage of HbA1c | Placebo | 0.75 mg Dulaglutide | 1.5 mg Dulaglutide |
|---|---|---|---|
| Change From Baseline in HbA1c (Individual Doses) at Week 26 | 0.5 ± 0.24 | -0.5 ± 0.22 | -1.0 ± 0.22 |
Fasting blood glucose is a test to determine how much glucose (sugar) is in a blood sample after an overnight fast. Least squares (LS) means were calculated using a mixed-effects model for repeated measures (MMRM) analysis and adjusted by baseline, strata, treatment, time, treatment\*time, (Type III sum of squares). Variance-Covariance structure = Unstructured (for actual value) / Unstructured (for change from baseline). Strata refer to: insulin use + metformin use + baseline HbA1c group \[ less than (\<) 8%, greater than or equal to (\>=) 8%).
| millimoles per liter (mmol/L) | Placebo | 0.75 mg Dulaglutide | 1.5 mg Dulaglutide | Pooled Dulaglutide |
|---|---|---|---|---|
| Change From Baseline in Fasting Blood Glucose (FBG) at Week 26 | 0.96 ± 0.45 | -0.47 ± 0.41 | -1.54 ± 0.41 | -1.03 ± 0.29 |
The percentage of participants was calculated by dividing the number of participants reaching target HbA1c by the total number of participants analyzed, multiplied by 100.
| percentage of participants | Placebo | 0.75 mg Dulaglutide | 1.5 mg Dulaglutide | Pooled Dulaglutide |
|---|---|---|---|---|
| Percentage of Participants With HbA1c ≤7.0% | 18.42 | 60.00 | 53.19 | 56.52 |
BMI is an estimate of body fat based on body weight divided by height squared. LS mean were calculated using a MMRM analysis and adjusted by baseline, strata, treatment, time, treatment\*time, (Type III sum of squares). Variance-Covariance structure = Unstructured (for actual value) / Unstructured (for change from baseline). Strata refer to: insulin use + metformin use + baseline HbA1c group (\< 8%, \>= 8%).
| kilograms/square meter (kg/m^2) | Placebo | 0.75 mg Dulaglutide | 1.5 mg Dulaglutide | Pooled Dulaglutide |
|---|---|---|---|---|
| Change From Baseline in Body Mass Index (BMI) at Week 26 | -0.0 ± 0.21 | -0.2 ± 0.20 | -0.1 ± 0.19 | -0.1 ± 0.14 |
Summary and analysis of Incidence of all hypoglycemia with Plasma Glucose \<54mg/dL.
| percentage of participants | Placebo | 0.75 mg Dulaglutide | 1.5 mg Dulaglutide |
|---|---|---|---|
| Percentage of Participants With Self-Reported Events of Hypoglycemia | 1.96 | 3.92 | 3.85 |
Percentage of Participants Requiring Rescue for Severe, Persistent Hyperglycemia was summarized.
| percentage of participants | Placebo | 0.75 mg Dulaglutide | 1.5 mg Dulaglutide | Pooled Dulaglutide |
|---|---|---|---|---|
| Percentage of Participants Requiring Rescue for Severe, Persistent Hyperglycemia | 17.6 | 3.9 | 1.9 | 2.9 |
The number of participants with pancreatitis confirmed by adjudication is summarized cumulatively at 26 weeks. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.
| participants | Placebo | 0.75 mg Dulaglutide | 1.5 mg Dulaglutide | Pooled Dulaglutide |
|---|---|---|---|---|
| Number of Participants With Adjudicated Pancreatitis | 0 | 0 | 0 | 0 |
Serum Amylase (total and pancreas-derived) and lipase concentrations were measured.
| Units/Liter (U/L) | Placebo | 0.75 mg Dulaglutide | 1.5 mg Dulaglutide | Pooled Dulaglutide |
|---|---|---|---|---|
| Serum Amylase | 0.09 ± 17.36 | 4.80 ± 9.39 | 6.50 ± 8.91 | 5.64 ± 9.15 |
| Serum Amylase, Pancreatic | 0.60 ± 9.94 | 1.77 ± 4.72 | 2.90 ± 6.10 | 2.32 ± 5.45 |
| Serum Lipase | 2.23 ± 31.99 | 4.37 ± 8.28 | 3.88 ± 6.63 | 4.12 ± 7.47 |
Number of Participants with Thyroid Treatment-Emergent Adverse Events were summarized.
| Participants | Placebo | 0.75 mg Dulaglutide | 1.5 mg Dulaglutide | Pooled Dulaglutide |
|---|---|---|---|---|
| Number of Participants With Thyroid Treatment-Emergent Adverse Events | 0 | 0 | 0 | 0 |
Change from Baseline in Serum Calcitonin was evaluated.
| nanograms per liter (ng/L) | Placebo | 0.75 mg Dulaglutide | 1.5 mg Dulaglutide | Pooled Dulaglutide |
|---|---|---|---|---|
| Change From Baseline in Serum Calcitonin at Week 26 | 0.38 ± 1.70 | 0.28 ± 0.72 | 0.10 ± 0.50 | 0.19 ± 0.62 |
The percentage of Participants with Allergic and hypersensitivity reactions that were considered possibly related to study drug by the investigator are presented. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.
| percentage of participants | Placebo | 0.75 mg Dulaglutide | 1.5 mg Dulaglutide | Pooled Dulaglutide |
|---|---|---|---|---|
| Percentage of Participants With Allergic, Hypersensitivity Reactions | 2.0 | 3.9 | 1.9 | 2.9 |
The percentage of participants with at least one treatment-emergent injection site reaction is presented. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.
| percentage of participants | Placebo | 0.75 mg Dulaglutide | 1.5 mg Dulaglutide | Pooled Dulaglutide |
|---|---|---|---|---|
| Percentage of Participants With Injection Site Reactions | 9.8 | 9.8 | 7.7 | 8.7 |
Dulaglutide anti-drug antibodies (ADA) were assessed at baseline, Weeks 26 and 56. A participant was considered to have treatment-emergent (TE) dulaglutide ADAs if the participant had at least 1 titer that was TE relative to baseline, defined as a 4-fold or greater increase in titer from baseline measurement.
| participants | Placebo/0.75 mg Dulaglutide | 0.75 mg Dulaglutide | 1.5 mg Dulaglutide |
|---|---|---|---|
| Number of Participants With Anti-Dulaglutide Antibodies | 3 | 3 | 3 |
PK: Maximum Concentration of Dulaglutide at steady-state (Cmax,ss) was derived by a population pharmacokinetics approach. As part of addendum, additional PK samples were taken at week 9.
| nanograms per milliliter (ng/mL) | 0.75 mg Dulaglutide | 1.5 mg Dulaglutide |
|---|---|---|
| Pharmacokinetics (PK): Maximum Concentration of Dulaglutide at Steady-state (Cmax,ss) | 31 (28.4 to 33.5) | 62 (56.9 to 67.2) |
PK: Area Under the Concentration Time Curve over a 1-week interval of Dulaglutide at Steady-State \[AUC(0-168)ss\] was derived by a population pharmacokinetics approach. As part of addendum, additional PK samples were taken at week 9.
| nanogram*hour per milliliter (ng*h/ mL) | 0.75 mg Dulaglutide | 1.5 mg Dulaglutide |
|---|---|---|
| PK: Area Under the Concentration Time Curve Over a 1-week Interval of Dulaglutide at Steady-State [AUC(0-168)ss] | 4170 (3770 to 4510) | 8350 (7640 to 9070) |
Collected over Up To 56 Weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo: Double-Blind Period | 0/51 (0%) | 3/51 (5.9%) | 26/51 (51%) |
| 0.75 mg Dulaglutide: Double-Blind Period | 0/51 (0%) | 1/51 (2%) | 25/51 (49%) |
| 1.5 mg Dulaglutide: Double-Blind Period | 0/52 (0%) | 1/52 (1.9%) | 28/52 (53.8%) |
| Placebo/0.75 mg Dulaglutide: Open Label Extension (OLE) | 0/47 (0%) | 0/47 (0%) | 18/47 (38.3%) |
| 0.75 mg Dulaglutide: OLE | 0/49 (0%) | 1/49 (2%) | 16/49 (32.7%) |
| 1.5 mg Dulaglutide: OLE | 0/50 (0%) | 2/50 (4%) | 20/50 (40%) |
| Event | Placebo: Double-Blind Period | 0.75 mg Dulaglutide: Double-Blind Period | 1.5 mg Dulaglutide: Double-Blind Period | Placebo/0.75 mg Dulaglutide: Open Label Extension (OLE) | 0.75 mg Dulaglutide: OLE | 1.5 mg Dulaglutide: OLE |
|---|---|---|---|---|---|---|
| Pilonidal cystInfections and infestations | 0/51 | 0/51 | 0/52 | 0/47 | 1/49 | 0/50 |
| PyelonephritisInfections and infestations | 0/51 | 0/51 | 0/52 | 0/47 | 0/49 | 1/50 |
| Carbon monoxide poisoningInjury, poisoning and procedural complications | 0/51 | 0/51 | 0/52 | 0/47 | 0/49 | 1/50 |
| Right ventricular failureCardiac disorders | 1/51 | 0/51 | 0/52 | 0/47 | 0/49 | 0/50 |
| Nonalcoholic fatty liver diseaseHepatobiliary disorders | 0/51 | 1/51 | 0/52 | 0/47 | 0/49 | 0/50 |
| Genital herpesInfections and infestations | 1/51 | 0/51 | 0/52 | 0/47 | 0/49 | 0/50 |
| Diabetic ketoacidosisMetabolism and nutrition disorders | 1/51 | 0/51 | 0/52 | 0/47 | 0/49 | 0/50 |
| Suicide attemptPsychiatric disorders | 1/51 | 0/51 | 0/52 | 0/47 | 0/49 | 0/50 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 1/51 | 0/51 | 0/52 | 0/47 | 0/49 | 0/50 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 1/51 | 0/51 | 0/52 | 0/47 | 0/49 | 0/50 |
| Event | Placebo: Double-Blind Period | 0.75 mg Dulaglutide: Double-Blind Period | 1.5 mg Dulaglutide: Double-Blind Period | Placebo/0.75 mg Dulaglutide: Open Label Extension (OLE) | 0.75 mg Dulaglutide: OLE | 1.5 mg Dulaglutide: OLE |
|---|---|---|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 7/51 | 8/51 | 11/52 | 0/47 | 1/49 | 6/50 |
| VomitingGastrointestinal disorders | 2/51 | 9/51 | 7/52 | 4/47 | 4/49 | 5/50 |
| NauseaGastrointestinal disorders | 4/51 | 7/51 | 8/52 | 1/47 | 3/49 | 6/50 |
| HeadacheNervous system disorders | 5/51 | 7/51 | 8/52 | 2/47 | 5/49 | 5/50 |
| Upper respiratory tract infectionInfections and infestations | 4/51 | 2/51 | 6/52 | 3/47 | 0/49 | 1/50 |
| Abdominal pain upperGastrointestinal disorders | 4/51 | 3/51 | 5/52 | 2/47 | 0/49 | 5/50 |
| NasopharyngitisInfections and infestations | 3/51 | 5/51 | 2/52 | 4/47 | 1/49 | 3/50 |
| DysmenorrhoeaReproductive system and breast disorders | 1/41 | 1/35 | 2/34 | 0/38 | 0/34 | 3/34 |
| GastroenteritisInfections and infestations | 2/51 | 1/51 | 3/52 | 4/47 | 0/49 | 3/50 |
| Abdominal painGastrointestinal disorders | 3/51 | 4/51 | 1/52 | 0/47 | 3/49 | 3/50 |
All randomized participants.
| Age, Continuous(years) | Placebo/0.75 mg Dulaglutide | 0.75 mg Dulaglutide | 1.5 mg Dulaglutide | Total |
|---|---|---|---|---|
| Mean | 14.20 ± 2.08 | 14.70 ± 2.21 | 14.70 ± 1.81 | 14.50 ± 2.04 |
| Sex: Female, Male(Participants) | Placebo/0.75 mg Dulaglutide | 0.75 mg Dulaglutide | 1.5 mg Dulaglutide | Total |
|---|---|---|---|---|
| Female | 41 | 35 | 34 | 110 |
| Male | 10 | 16 | 18 | 44 |
| Ethnicity (NIH/OMB)(Participants) | Placebo/0.75 mg Dulaglutide | 0.75 mg Dulaglutide | 1.5 mg Dulaglutide | Total |
|---|---|---|---|---|
| Hispanic or Latino | 26 | 31 | 28 | 85 |
| Not Hispanic or Latino | 25 | 18 | 22 | 65 |
| Unknown or Not Reported | 0 | 2 | 2 | 4 |
| Race (NIH/OMB)(Participants) | Placebo/0.75 mg Dulaglutide | 0.75 mg Dulaglutide | 1.5 mg Dulaglutide | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 6 | 6 | 4 | 16 |
| Asian | 11 | 4 | 4 | 19 |
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 0 | 1 |
| Black or African American | 5 | 9 | 9 | 23 |
| White | 25 | 29 | 30 | 84 |
| More than one race | 3 | 1 | 3 | 7 |
| Unknown or Not Reported | 0 | 2 | 2 | 4 |
| Region of Enrollment(Participants) | Placebo/0.75 mg Dulaglutide | 0.75 mg Dulaglutide | 1.5 mg Dulaglutide | Total |
|---|---|---|---|---|
| Brazil | 4 | 7 | 5 | 16 |
| France | 0 | 2 | 2 | 4 |
| Germany | 2 | 1 | 0 | 3 |
| India | 3 | 4 | 4 | 11 |
| Mexico | 14 | 12 | 10 | 36 |
| Puerto Rico | 0 | 1 | 1 | 2 |
| Saudi Arabia | 2 | 0 | 1 | 3 |
| Turkey | 1 | 1 | 1 | 3 |
| United Kingdom | 3 | 2 | 0 | 5 |
| United States | 22 | 21 | 28 | 71 |
| Percentage of Hemoglobin A1c (HbA1c) at Baseline(Percentage of HbA1c) | Placebo/0.75 mg Dulaglutide | 0.75 mg Dulaglutide | 1.5 mg Dulaglutide | Total |
|---|---|---|---|---|
| Mean | 8.14 ± 1.12 | 7.92 ± 1.27 | 8.16 ± 1.39 | 8.08 ± 1.26 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.
Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Data sharing details ↗ · www.vivli.org
Ran from Dec 2016 to primary completion in Jun 2021, 53 months.
Results were first posted in Jul 2022, 1 year after primary completion.
Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 53 months is above that.
Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dulaglutide